

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME John Leland Johnson		POSITION TITLE Professor of Medicine and International Health	
eRA COMMONS USER NAME (credential, e.g., agency login)			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION		DEGREE (if applicable)	YEAR(s)
Gannon University		B.S.	1977
University of Pittsburgh School of Medicine		M.D.	1981
			FIELD OF STUDY
			Biology
			University of Pittsburgh School of Medicine

### A. Positions and Honors.

1981-1985 Intern and Resident, Vanderbilt University Medical Center, Nashville, TN  
1985-1987 Pulmonary Fellow, Case Western Reserve University, Cleveland, OH  
1987-1988 Senior Instructor; 1988-1999; Assistant Professor; 1999-2006 Associate Professor; 2006-Present  
Professor of Medicine and International Health, Case Western Reserve University, Cleveland, OH

### B. Selected peer-reviewed publications (in chronological order).

Johnson JL, Shiratsuchi H, Toba H, Ellner JJ. Preservation of monocyte effector functions against *Mycobacterium avium-M. intracellulare* in patients with AIDS. *Infect Immun* 1991; 59:3639-3645.

Shiratsuchi H, Johnson JL, Ellner JJ. Bidirectional effect of cytokines on the intracellular growth of *Mycobacterium avium* in human monocytes. *J Immunol* 1991; 146:3165-3170.

Daifuku R, Panacek EA, Haenftling K, Swenson WK, Prescott AW, Johnson JL. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis. *Human Antibod Hybridomas* 1993; 4:36-38.

Okwera A, Whalen C, Byekwaso F, Vjecha M, Johnson J, Huebner R, Mugerwa R, Ellner J. Randomized trial of thiacetazone and rifampin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. *Lancet* 1994;344:1323-1328.

Shiratsuchi H, Johnson JL, Toossi Z, Ellner JJ. Modulation of the effector function of human monocytes for *Mycobacterium avium* by human immunodeficiency virus-1 envelope glycoprotein gp120. *J Clin Invest* 1994; 93:885-891.

Hom DL, Johnson JL, Mugenyi P, Byaruhanga R, Kityo C, Svilar GM, Vjecha M, Mugerwa RD, Ellner JJ. HIV-1 risk and vaccine acceptability in the Ugandan military. *J Acquir Immun Defic Syndr Hum Retrovirol* 1997; 15:375-380.

Johnson JL, Shiratsuchi H, Toossi Z, Ellner JJ. Altered IL-1 expression and compartmentalization in monocytes from patients with AIDS stimulated with *Mycobacterium avium* complex. *J Clin Immunol* 1997;17:387-395.

Purvis SF, Katongole-Mbidde E, Johnson JL, Leonard DGB, Byabazaire N, Luckey C, Schick HE, Elmets CA, Giam CZ. High incidence of Kaposi's sarcoma associated herpesvirus (KSHV) and Epstein-Barr virus in tumor lesions and peripheral blood mononuclear cells from patients with Kaposi's sarcoma in Uganda. *J Infect Dis* 1997;175:947-950.

Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugenyi P, Mugerwa RD, Ellner JJ. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. *N Engl J Med* 1997;337:801-808.

Wallis RS, Patil S, Cheon SH, Edmonds K, Phillips M, Perkins MD, Joloba M, Namale A, Johnson JL, Teixeira L, Dietze R, Siddiqi S, Mugerwa RD, Eisenach K, Ellner JJ. Drug tolerance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1999;43:2600-2606.

Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander S, Robertson S, Wallis RS, Edmonds K, Okwera A, Mugerwa R, Peters P, Ellner JJ. Depressed T-cell interferon responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. *J Infect Dis* 1999; 180:2069-2073.

- Johnson JL, Kanya RM, Okwera A, Loughlin AM, Nyole S, Hom D, Wallis RS, Hirsch CM, Wolski KW, Foulds J, Mugerwa RD, Ellner JJ. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-Human Immunodeficiency Virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. *J Infect Dis* 2000;181:1304-1312.
- Wallis RS, Perkins MD, Phillips M, Joloba M, Namale A, Johnson JL, Whalen CC, Teixeira L, Dietze R, Mugerwa R, Eisenach K, Ellner JJ. Predicting the outcome of therapy for pulmonary tuberculosis. *Am J Respir Crit Care* 2000;161:1076-1080.
- Joloba ML, Johnson JL, Namale A, Morrissey A, Assegghai AE, Mugerwa RD, Ellner JJ, Eisenach KD. Quantitative sputum bacillary load during rifampicin-containing short course chemotherapy in human immunodeficiency virus- infected and non-infected adults with pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2000;4:528-536.
- Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, Michael NL, Mugerwa RD, Ellner JJ. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. *AIDS* 2000;14:1219-1228.
- Johnson JL, Okwera A, Nsubuga P, Nakibali JG, Whalen CC, Hom D, Cave MD, Yang Z, Mugerwa RD, Ellner JJ. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. *Int J Tuberc Lung Dis* 2000;4:1032-1040.
- Hertoghe T, Wajja A, Ntambi L, Okwera A, Aziz MA, Hirsch C, Johnson J, Toossi Z, Mugerwa R, Mugenyi P, Colebunders R, Ellner J, Vanham G. T cell activation, apoptosis and regulatory cytokine production in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). *Clin Exp Immunol* 2000;122:350-357.
- Hirsch CS, Toossi Z, Johnson JL, Luzze H, Ntambi L, Peters P, McHugh M, Okwera A, Joloba M, Mugenyi P, Mugerwa RD, Terubuh P, Ellner JJ. Augmentation of apoptosis and IFN- $\gamma$  production at the site of active MTB infection in human tuberculosis. *J Infect Dis* 2001;183:779-788.
- Hodsdon WS, Luzze H, Hurst TJ, Quigley MA, Kyosiimire J, Namujju PB, Johnson JL, Kaleebu P, Okwera A, Elliott AM. HIV-1-related pleural tuberculosis: elevated production of IFN- $\gamma$ , but failure of immunity to *M. tuberculosis*. *AIDS* 2001;15:467-475.
- Wallis RS, Phillips M, Johnson JL, Teixeira L, Rocha LM, Maciel E, Rose L, Wells C, Palaci M, Dietze R, Eisenach K, Ellner JJ. Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: Potential surrogate marker in tuberculosis chemotherapy trials. *Antimicrob Agents Chemother* 2001;45:1302-1304.
- Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, do Valle Dettoni V, Canedo Rocha LM, Debanne S, Talbot E, Dietze R. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2001;5:321-328.
- Mayanja-Kizza H, Johnson JL, Hirsch CS, Peters P, Surewicz K, Wu M, Nalugwa G, Mubiru F, Luzze H, Wajja A, Aung H, Ellner JJ, Whalen C, Toossi Z. Macrophage-activating cytokines in human immunodeficiency virus type 1-infected and -uninfected patients with pulmonary tuberculosis. *J Infect Dis* 2001;183:1805-1809.
- Dietze R, Teixeira L, Canedo Rocha LM, Palaci M, Johnson JL, Wells C, Rose L, Eisenach K, Ellner JJ. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. *Antimicrob Agents Chemother* 2001;45:1972-1976.
- Luzze H, Elliott AM, Joloba ML, Odida ML, Oweka-Onyee J, Nakiyingi J, Quigley M, Hirsch C, Mugerwa RD, Okwera A, Johnson JL. Evaluation of suspected tuberculous pleurisy: Clinical and diagnostic findings in HIV-1-positive and HIV-negative adults in Uganda. *Int J Tuberc Lung Dis* 2001;5:746-753.
- Toossi Z, Johnson JL, Kanost AR, Wu M, Luzze H, Peters P, Okwera A, Joloba M, Mugenyi P, Mugerwa RD, Aung H, Ellner JJ, Hirsch CS. Increased replication of Human Immunodeficiency Virus-1 (HIV-1) at sites of *M. tuberculosis* infection: potential mechanisms of viral activation. *J Acquir Immune Defic Syndr Hum Retrovirol* 2001;28:1-8.
- Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo C, Nsubuga P, Nakibali JG, Loughlin AM, Mugenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. *AIDS* 2001;15 (16):2137-2147.
- Nshuti L, Neuhauser D, Johnson JL, Adatu F, Whalen CC. The role of private providers in the care of tuberculosis patients in Uganda. *Int J Tuberc Lung Dis* 2001;5(11):1006-1012.

- Collins KR, Quinones-Mateu ME, Wu M, Luzze H, Johnson JL, Hirsch C, Toossi Z, Arts EJ. Human immunodeficiency virus type 1 (HIV-1) quasiespecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. *J Virol* 2002;76:1697-1706.
- Ribeiro-Rodrigues R, Co TR, Johnson JL, Ribeiro F, Palaci M, Sá RT, Maciel EL, Lima FEP, Dettoni V, Toossi Z, Boom WH, Dietze R, Ellner JJ, Hirsch CS. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers mycobacterial clearance. *Clin Diagn Lab Immunol* 2002;9: 818-823.
- Wallis RS, Vinhas SA, Johnson JL, Ribeiro FC, Palaci M, Peres RL, Sa RT, Dietze R, Chiunda A, Eisenach K, Ellner JJ. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. *J Infect Dis* 2003;187:270-278.
- Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali J, Drzayich Jankus D, Eisenach KD, Boom WH, Ellner JJ, Mugerwa RD. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. *Am J Respir Crit Care Med* 2003; 168:185-191.
- Wallis RS, Kyambadde P, Johnson JL, Horter H, Kittle R, Pohle M, Ducar C, Millard M, Mayanja-Kizza H, Whalen C, Okwera A. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. *AIDS* 2004;18:257-264.
- Islam N, Kanost AR, Teixeira L, Johnson J, Hejal R, Aung H, Wilkinson RJ, Hirsch CS, Toossi Z. Role of cellular activation and Tumor Necrosis Factor- alpha in the early expression of Mycobacterium tuberculosis 85B mRNA in human alveolar macrophages. *J Infect Dis* 2004;190:341-351.
- Johnson JL, Okwera A, Horter L, Whalen CC, Mugerwa RD. Rifampicin-containing regimens for the treatment of latent tuberculosis infection also prevented diarrheal illnesses in HIV-infected Ugandan adults. *AIDS* 2004;18:706-708.
- Elliott AM, Luzze H, Quigley MA, Nakiyingi J, Kyaligonza S, Namujju PB, Ducar C, Ellner JJ, Whitworth JAG, Mugerwa R, Johnson JL, Okwera A. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. *J Infect Dis* 2004;190:869-878.
- Johnson JL, Nunn AJ, Fourie PB, Ormerod LP, Mugerwa RD, Chintu C, Mwinga A, Ngwira B, Onyebujoh P, Zumla A. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. *Int J Tuberc Lung Dis* 2004;8:1348-1354.
- Aung H, Wu M, Johnson JL, Hirsch CS, Toossi Z. Bioactivation of latent transforming growth factor beta1 by Mycobacterium tuberculosis in human mononuclear phagocytes. *Scand J Immunol* 2005;61:558-65.
- Hirsch CS, Johnson JL, Okwera A, Kanost RA, Wu M, Peters P, Muhumuza M, Mayanja-Kizza H, Mugerwa RD, Mugenyi P, Ellner JJ, Toossi Z. Mechanisms of apoptosis of T-cells in human tuberculosis. *J Clin Immunol* 2005;25:353-64.
- Wallis RS, Johnson JL. The role of surrogate markers in the clinical evaluation of anti-tuberculous chemotherapy. *Current Medicinal Chemistry: Anti-Infective Agents* 2005;4:287-294.
- Mayanja Kizza H, Rodriguez B, Quinones-Mateu M, Mirza M, Aung H, Yen-Lieberman B, Starkey C, Horter L, Peters P, Baseke J, Johnson JL, Toossi Z. Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. *Clin Diagn Lab Immunol* 2005;12:1298-1304.
- Okwera A, Johnson JL, Nsubuga P, Luzze H, Kayanja H, Cohn D, Nunn P, Ellner JJ, Whalen CC, Mugerwa RD. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. *Int J Tuberc Lung Dis* 2006;10:39-44.
- Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 2006;10:605-612.
- Teixeira L, Johnson JL. Prosthetic joint infection: when to suspect it, how to manage it. *Geriatrics*. 2007;62:18-22.
- Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, Maciel EL, do Valle Dettoni V, Horter L, Boom WH, Johnson JL, Eisenach KD. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. *J Clin Microbiol*. 2007;45:4064-4066.
- Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis. *Antimicrob Agents Chemother*. 2008;52:852-857.

### C. Research Support

NIAID

RFP (AI45244/AI-95383/AI-70022)

09/30/94-04/30/07; (renewed 05/01/07 - 04/30/14)

#### **“Tuberculosis Research and Prevention Unit”**

The purpose of this international contract is to perform multi-disciplinary investigations of the transmission, immunopathogenesis, and microbiology of tuberculosis and to conduct phase I/II/III clinical trials of new drugs, vaccines, immunotherapeutic agents and regimens for tuberculosis prevention and treatment. The contract has 3 international trial sites (Makerere University, Kampala, Uganda; Federal University of Espírito Santo, Vitoria, Brazil; Tropical Diseases Foundation, Makati City, Philippines). Phase II clinical trials evaluating adjunctive immunotherapy with heat-killed *M. vaccae* and recombinant human interleukin-2 have been completed in Uganda. A phase I/II trial assessing the early bactericidal activity of rifalazil (KRM-1648), a new rifamycin derivative, was conducted in Brazil. Several trials evaluating potential surrogate marker of host immunological and microbiological responses during anti-TB treatment have been conducted in Brazil and Uganda. Current studies include a phase III randomized clinical trial in Uganda, Brazil and the Philippines to assess whether TB treatment can be shortened from 6 to 4 months in HIV-non-infected adults with non-cavitary tuberculosis who convert their sputum cultures to negative after 2 months of treatment and a phase IIb trial in Brazil to compare the early bactericidal activity of 3 new fluoroquinolones and linezolid. Principal Investigator: W. Henry Boom MD; John L. Johnson, M.D., Co-Investigator and Component Leader - Clinical Trials

CDC

Contract (200-2003-01441

09/15/03-09/14/09

#### **“Tuberculosis Trials Consortium (TBTC) International Sites”**

The Tuberculosis Trials Consortium (TBTC) is a collaboration of international clinical investigators whose mission is to conduct programmatically relevant research concerning the diagnosis, clinical management, and prevention of TB infection and disease. Initially constituted at US and Canadian sites, TBTC expanded in 2003 to include international sites in Brazil, Uganda, Spain and South Africa. Study 27, a randomized, double dummy phase IIb trial to assess the activity and tolerability of moxifloxacin substituted for ethambutol during the first 2 months of treatment in HIV-infected and non-infected adults with smear positive TB was completed in 2005. Study NAA is an ongoing study of the ability of nucleic acid amplification tests to predict tuberculosis relapse after treatment in HIV-infected and non-infected adults. Study 28, a randomized, double dummy phase IIb trial to assess the activity and tolerability of moxifloxacin substituted for isoniazid during the first 2 months of therapy in HIV-infected and non-infected adults with TB, was initiated in February 2006.

Principal Investigator: John L. Johnson, M.D.

Family Health International - NO1-HD-0-3310-502-2

(Salata, PI)

10/1/00 - 9/30/10

#### **“Hormonal Contraception and the Risk of HIV Acquisition”**

The major goals of this study are to assess whether hormonal contraception use in women in Uganda, Zimbabwe and Thailand increases HIV transmission.

Role: Investigator